Table of Contents
EXECUTIVE SUMMARY
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Global Generics
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Asia-Pacific
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Europe
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Australia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The Netherlands
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Spain
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: Global generics market value: $ billion, 2012–16
Table 2: Global generics market volume: % of total pharma volume, 2012–16
Table 3: Global generics market geography segmentation: $ billion, 2016
Table 4: Global generics market value forecast: $ billion, 2016–21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016–21
Table 6: Asia-Pacific generics market value: $ billion, 2012–16
Table 7: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
Table 8: Asia–Pacific generics market geography segmentation: $ billion, 2016
Table 9: Asia-Pacific generics market value forecast: $ billion, 2016–21
Table 10: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
Table 11: Europe generics market value: $ billion, 2012–16
Table 12: Europe generics market volume: % of total pharma volume, 2012–16
Table 13: Europe generics market geography segmentation: $ billion, 2016
Table 14: Europe generics market value forecast: $ billion, 2016–21
Table 15: Europe generics market volume forecast: % of total pharma volume, 2016–21
Table 16: France generics market value: $ billion, 2012–16
Table 17: France generics market volume: % of total pharma volume, 2012–16
Table 18: France generics market geography segmentation: $ billion, 2016
Table 19: France generics market value forecast: $ billion, 2016–21
Table 20: France generics market volume forecast: % of total pharma volume, 2016–21
Table 21: France size of population (million), 2012–16
Table 22: France gdp (constant 2005 prices, $ billion), 2012–16
Table 23: France gdp (current prices, $ billion), 2012–16
Table 24: France inflation, 2012–16
Table 25: France consumer price index (absolute), 2012–16
Table 26: France exchange rate, 2012–16
Table 27: Germany generics market value: $ billion, 2012–16
Table 28: Germany generics market volume: % of total pharma volume, 2012–16
Table 29: Germany generics market geography segmentation: $ billion, 2016
Table 30: Germany generics market value forecast: $ billion, 2016–21
Table 31: Germany generics market volume forecast: % of total pharma volume, 2016–21
Table 32: Germany size of population (million), 2012–16
Table 33: Germany gdp (constant 2005 prices, $ billion), 2012–16
Table 34: Germany gdp (current prices, $ billion), 2012–16
Table 35: Germany inflation, 2012–16
Table 36: Germany consumer price index (absolute), 2012–16
Table 37: Germany exchange rate, 2012–16
Table 38: Italy generics market value: $ billion, 2012–16
Table 39: Italy generics market volume: % of total pharma volume, 2012–16
Table 40: Italy generics market geography segmentation: $ billion, 2016
Table 41: Italy generics market value forecast: $ billion, 2016–21
Table 42: Italy generics market volume forecast: % of total pharma volume, 2016–21
Table 43: Italy size of population (million), 2012–16
Table 44: Italy gdp (constant 2005 prices, $ billion), 2012–16
Table 45: Italy gdp (current prices, $ billion), 2012–16
Table 46: Italy inflation, 2012–16
Table 47: Italy consumer price index (absolute), 2012–16
Table 48: Italy exchange rate, 2012–16
Table 49: Japan generics market value: $ billion, 2012–16
Table 50: Japan generics market volume: % of total pharma volume, 2012–16
Table 51: Japan generics market geography segmentation: $ billion, 2016
Table 52: Japan generics market value forecast: $ billion, 2016–21
Table 53: Japan generics market volume forecast: % of total pharma volume, 2016–21
Table 54: Japan size of population (million), 2012–16
Table 55: Japan gdp (constant 2005 prices, $ billion), 2012–16
Table 56: Japan gdp (current prices, $ billion), 2012–16
Table 57: Japan inflation, 2012–16
Table 58: Japan consumer price index (absolute), 2012–16
Table 59: Japan exchange rate, 2012–16
Table 60: Australia generics market value: $ billion, 2012–16
Table 61: Australia generics market volume: % of total pharma volume, 2012–16
Table 62: Australia generics market geography segmentation: $ billion, 2016
Table 63: Australia generics market value forecast: $ billion, 2016–21
Table 64: Australia generics market volume forecast: % of total pharma volume, 2016–21
Table 65: Australia size of population (million), 2012–16
Table 66: Australia gdp (constant 2005 prices, $ billion), 2012–16
Table 67: Australia gdp (current prices, $ billion), 2012–16
Table 68: Australia inflation, 2012–16
Table 69: Australia consumer price index (absolute), 2012–16
Table 70: Australia exchange rate, 2012–16
Table 71: Canada generics market value: $ billion, 2012–16
Table 72: Canada generics market volume: % of total pharma volume, 2012–16
Table 73: Canada generics market geography segmentation: $ billion, 2016
Table 74: Canada generics market value forecast: $ billion, 2016–21
Table 75: Canada generics market volume forecast: % of total pharma volume, 2016–21
Table 76: Canada size of population (million), 2012–16
Table 77: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 78: Canada gdp (current prices, $ billion), 2012–16
Table 79: Canada inflation, 2012–16
Table 80: Canada consumer price index (absolute), 2012–16
Table 81: Canada exchange rate, 2012–16
Table 82: China generics market value: $ billion, 2012–16
Table 83: China generics market volume: % of total pharma volume, 2012–16
Table 84: China generics market geography segmentation: $ billion, 2016
Table 85: China generics market value forecast: $ billion, 2016–21
Table 86: China generics market volume forecast: % of total pharma volume, 2016–21
Table 87: China size of population (million), 2012–16
Table 88: China gdp (constant 2005 prices, $ billion), 2012–16
Table 89: China gdp (current prices, $ billion), 2012–16
Table 90: China inflation, 2012–16
Table 91: China consumer price index (absolute), 2012–16
Table 92: China exchange rate, 2012–16
Table 93: Netherlands generics market value: $ billion, 2012–16
Table 94: Netherlands generics market volume: % of total pharma volume, 2012–16
Table 95: Netherlands generics market geography segmentation: $ billion, 2016
Table 96: Netherlands generics market value forecast: $ billion, 2016–21
Table 97: Netherlands generics market volume forecast: % of total pharma volume, 2016–21
Table 98: Netherlands size of population (million), 2012–16
Table 99: Netherlands gdp (constant 2005 prices, $ billion), 2012–16
Table 100: Netherlands gdp (current prices, $ billion), 2012–16
Table 101: Netherlands inflation, 2012–16
Table 102: Netherlands consumer price index (absolute), 2012–16
Table 103: Netherlands exchange rate, 2012–16
Table 104: Spain generics market value: $ billion, 2012–16
Table 105: Spain generics market volume: % of total pharma volume, 2012–16
Table 106: Spain generics market geography segmentation: $ billion, 2016
Table 107: Spain generics market value forecast: $ billion, 2016–21
Table 108: Spain generics market volume forecast: % of total pharma volume, 2016–21
Table 109: Spain size of population (million), 2012–16
Table 110: Spain gdp (constant 2005 prices, $ billion), 2012–16
Table 111: Spain gdp (current prices, $ billion), 2012–16
Table 112: Spain inflation, 2012–16
Table 113: Spain consumer price index (absolute), 2012–16
Table 114: Spain exchange rate, 2012–16
Table 115: United Kingdom generics market value: $ billion, 2012–16
Table 116: United Kingdom generics market volume: % of total pharma volume, 2012–16
Table 117: United Kingdom generics market geography segmentation: $ billion, 2016
Table 118: United Kingdom generics market value forecast: $ billion, 2016–21
Table 119: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
Table 120: United Kingdom size of population (million), 2012–16
Table 121: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
Table 122: United Kingdom gdp (current prices, $ billion), 2012–16
Table 123: United Kingdom inflation, 2012–16
Table 124: United Kingdom consumer price index (absolute), 2012–16
Table 125: United Kingdom exchange rate, 2012–16
Table 126: United States generics market value: $ billion, 2012–16
Table 127: United States generics market volume: % of total pharma volume, 2012–16
Table 128: United States generics market geography segmentation: $ billion, 2016
Table 129: United States generics market value forecast: $ billion, 2016–21
Table 130: United States generics market volume forecast: % of total pharma volume, 2016–21
Table 131: United States size of population (million), 2012–16
Table 132: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 133: United States gdp (current prices, $ billion), 2012–16
Table 134: United States inflation, 2012–16
Table 135: United States consumer price index (absolute), 2012–16
Table 136: United States exchange rate, 2012–15
Table 137: Allergan plc: key facts
Table 138: Allergan plc: key financials ($)
Table 139: Allergan plc: key financial ratios
Table 140: Mylan Inc.: key facts
Table 141: Mylan Inc.: key financials ($)
Table 142: Mylan Inc.: key financial ratios
Table 143: Sandoz International GmbH: key facts
Table 144: Teva Pharmaceutical Industries Limited: key facts
Table 145: Teva Pharmaceutical Industries Limited: key financials ($)
Table 146: Teva Pharmaceutical Industries Limited: key financial ratios
Table 147: Sun Pharmaceutical Industries Ltd.: key facts
Table 148: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 149: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 150: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 151: Sanofi SA: key facts
Table 152: Sanofi SA: key financials ($)
Table 153: Sanofi SA: key financials (€)
Table 154: Sanofi SA: key financial ratios
Table 155: Les Laboratoires Servier: key facts
Table 156: STADA Arzneimittel AG: key facts
Table 157: STADA Arzneimittel AG: key financials ($)
Table 158: STADA Arzneimittel AG: key financials (€)
Table 159: STADA Arzneimittel AG: key financial ratios
Table 160: Daiichi Sankyo Co., Ltd.: key facts
Table 161: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 162: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 163: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 164: Sawai Pharmaceutical Co., Ltd.: key facts
Table 165: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 166: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 167: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 168: Aspen Pharmacare Holdings Ltd: key facts
Table 169: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 170: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 171: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 172: Apotex, Inc.: key facts
Table 173: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 174: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 175: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 176: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 177: Esteve Group: key facts

List of Figures
Figure 1: Global generics market value: $ billion, 2012–16
Figure 2: Global generics market volume: % of total pharma volume, 2012–16
Figure 3: Global generics market geography segmentation: % share, by value, 2016
Figure 4: Global generics market value forecast: $ billion, 2016–21
Figure 5: Global generics market volume forecast: % of total pharma volume, 2016–21
Figure 6: Forces driving competition in the global generics market, 2016
Figure 7: Drivers of buyer power in the global generics market, 2016
Figure 8: Drivers of supplier power in the global generics market, 2016
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 11: Drivers of degree of rivalry in the global generics market, 2016
Figure 12: Asia-Pacific generics market value: $ billion, 2012–16
Figure 13: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
Figure 14: Asia–Pacific generics market geography segmentation: % share, by value, 2016
Figure 15: Asia-Pacific generics market value forecast: $ billion, 2016–21
Figure 16: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016
Figure 23: Europe generics market value: $ billion, 2012–16
Figure 24: Europe generics market volume: % of total pharma volume, 2012–16
Figure 25: Europe generics market geography segmentation: % share, by value, 2016
Figure 26: Europe generics market value forecast: $ billion, 2016–21
Figure 27: Europe generics market volume forecast: % of total pharma volume, 2016–21
Figure 28: Forces driving competition in the generics market in Europe, 2016
Figure 29: Drivers of buyer power in the generics market in Europe, 2016
Figure 30: Drivers of supplier power in the generics market in Europe, 2016
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016
Figure 34: France generics market value: $ billion, 2012–16
Figure 35: France generics market volume: % of total pharma volume, 2012–16
Figure 36: France generics market geography segmentation: % share, by value, 2016
Figure 37: France generics market value forecast: $ billion, 2016–21
Figure 38: France generics market volume forecast: % of total pharma volume, 2016–21
Figure 39: Forces driving competition in the generics market in France, 2016
Figure 40: Drivers of buyer power in the generics market in France, 2016
Figure 41: Drivers of supplier power in the generics market in France, 2016
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016
Figure 44: Drivers of degree of rivalry in the generics market in France, 2016
Figure 45: Germany generics market value: $ billion, 2012–16
Figure 46: Germany generics market volume: % of total pharma volume, 2012–16
Figure 47: Germany generics market geography segmentation: % share, by value, 2016
Figure 48: Germany generics market value forecast: $ billion, 2016–21
Figure 49: Germany generics market volume forecast: % of total pharma volume, 2016–21
Figure 50: Forces driving competition in the generics market in Germany, 2016
Figure 51: Drivers of buyer power in the generics market in Germany, 2016
Figure 52: Drivers of supplier power in the generics market in Germany, 2016
Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016
Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016
Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016
Figure 56: Italy generics market value: $ billion, 2012–16
Figure 57: Italy generics market volume: % of total pharma volume, 2012–16
Figure 58: Italy generics market geography segmentation: % share, by value, 2016
Figure 59: Italy generics market value forecast: $ billion, 2016–21
Figure 60: Italy generics market volume forecast: % of total pharma volume, 2016–21
Figure 61: Forces driving competition in the generics market in Italy, 2016
Figure 62: Drivers of buyer power in the generics market in Italy, 2016
Figure 63: Drivers of supplier power in the generics market in Italy, 2016
Figure 64: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016
Figure 65: Factors influencing the threat of substitutes in the generics market in Italy, 2016
Figure 66: Drivers of degree of rivalry in the generics market in Italy, 2016
Figure 67: Japan generics market value: $ billion, 2012–16
Figure 68: Japan generics market volume: % of total pharma volume, 2012–16
Figure 69: Japan generics market geography segmentation: % share, by value, 2016
Figure 70: Japan generics market value forecast: $ billion, 2016–21
Figure 71: Japan generics market volume forecast: % of total pharma volume, 2016–21
Figure 72: Forces driving competition in the generics market in Japan, 2016
Figure 73: Drivers of buyer power in the generics market in Japan, 2016
Figure 74: Drivers of supplier power in the generics market in Japan, 2016
Figure 75: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016
Figure 76: Factors influencing the threat of substitutes in the generics market in Japan, 2016
Figure 77: Drivers of degree of rivalry in the generics market in Japan, 2016
Figure 78: Australia generics market value: $ billion, 2012–16
Figure 79: Australia generics market volume: % of total pharma volume, 2012–16
Figure 80: Australia generics market geography segmentation: % share, by value, 2016
Figure 81: Australia generics market value forecast: $ billion, 2016–21
Figure 82: Australia generics market volume forecast: % of total pharma volume, 2016–21
Figure 83: Forces driving competition in the generics market in Australia, 2016
Figure 84: Drivers of buyer power in the generics market in Australia, 2016
Figure 85: Drivers of supplier power in the generics market in Australia, 2016
Figure 86: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016
Figure 87: Factors influencing the threat of substitutes in the generics market in Australia, 2016
Figure 88: Drivers of degree of rivalry in the generics market in Australia, 2016
Figure 89: Canada generics market value: $ billion, 2012–16
Figure 90: Canada generics market volume: % of total pharma volume, 2012–16
Figure 91: Canada generics market geography segmentation: % share, by value, 2016
Figure 92: Canada generics market value forecast: $ billion, 2016–21
Figure 93: Canada generics market volume forecast: % of total pharma volume, 2016–21
Figure 94: Forces driving competition in the generics market in Canada, 2016
Figure 95: Drivers of buyer power in the generics market in Canada, 2016
Figure 96: Drivers of supplier power in the generics market in Canada, 2016
Figure 97: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
Figure 98: Factors influencing the threat of substitutes in the generics market in Canada, 2016
Figure 99: Drivers of degree of rivalry in the generics market in Canada, 2016
Figure 100: China generics market value: $ billion, 2012–16
Figure 101: China generics market volume: % of total pharma volume, 2012–16
Figure 102: China generics market geography segmentation: % share, by value, 2016
Figure 103: China generics market value forecast: $ billion, 2016–21
Figure 104: China generics market volume forecast: % of total pharma volume, 2016–21
Figure 105: Forces driving competition in the generics market in China, 2016
Figure 106: Drivers of buyer power in the generics market in China, 2016
Figure 107: Drivers of supplier power in the generics market in China, 2016
Figure 108: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 109: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 110: Drivers of degree of rivalry in the generics market in China, 2016
Figure 111: Netherlands generics market value: $ billion, 2012–16
Figure 112: Netherlands generics market volume: % of total pharma volume, 2012–16
Figure 113: Netherlands generics market geography segmentation: % share, by value, 2016
Figure 114: Netherlands generics market value forecast: $ billion, 2016–21
Figure 115: Netherlands generics market volume forecast: % of total pharma volume, 2016–21
Figure 116: Forces driving competition in the generics market in the Netherlands, 2016
Figure 117: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 118: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 119: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 120: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 121: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 122: Spain generics market value: $ billion, 2012–16
Figure 123: Spain generics market volume: % of total pharma volume, 2012–16
Figure 124: Spain generics market geography segmentation: % share, by value, 2016
Figure 125: Spain generics market value forecast: $ billion, 2016–21
Figure 126: Spain generics market volume forecast: % of total pharma volume, 2016–21
Figure 127: Forces driving competition in the generics market in Spain, 2016
Figure 128: Drivers of buyer power in the generics market in Spain, 2016
Figure 129: Drivers of supplier power in the generics market in Spain, 2016
Figure 130: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016
Figure 131: Factors influencing the threat of substitutes in the generics market in Spain, 2016
Figure 132: Drivers of degree of rivalry in the generics market in Spain, 2016
Figure 133: United Kingdom generics market value: $ billion, 2012–16
Figure 134: United Kingdom generics market volume: % of total pharma volume, 2012–16
Figure 135: United Kingdom generics market geography segmentation: % share, by value, 2016
Figure 136: United Kingdom generics market value forecast: $ billion, 2016–21
Figure 137: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
Figure 138: Forces driving competition in the generics market in the United Kingdom, 2016
Figure 139: Drivers of buyer power in the generics market in the United Kingdom, 2016
Figure 140: Drivers of supplier power in the generics market in the United Kingdom, 2016
Figure 141: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016
Figure 142: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016
Figure 143: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016
Figure 144: United States generics market value: $ billion, 2012–16
Figure 145: United States generics market volume: % of total pharma volume, 2012–16
Figure 146: United States generics market geography segmentation: % share, by value, 2016
Figure 147: United States generics market value forecast: $ billion, 2016–21
Figure 148: United States generics market volume forecast: % of total pharma volume, 2016–21
Figure 149: Forces driving competition in the generics market in the United States, 2016
Figure 150: Drivers of buyer power in the generics market in the United States, 2016
Figure 151: Drivers of supplier power in the generics market in the United States, 2016
Figure 152: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
Figure 153: Factors influencing the threat of substitutes in the generics market in the United States, 2016
Figure 154: Drivers of degree of rivalry in the generics market in the United States, 2016
Figure 155: Allergan plc: revenues & profitability
Figure 156: Allergan plc: assets & liabilities
Figure 157: Mylan Inc.: revenues & profitability
Figure 158: Mylan Inc.: assets & liabilities
Figure 159: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 160: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 161: Sun Pharmaceutical Industries Ltd.: revenues & profitability
Figure 162: Sun Pharmaceutical Industries Ltd.: assets & liabilities
Figure 163: Sanofi SA: revenues & profitability
Figure 164: Sanofi SA: assets & liabilities
Figure 165: STADA Arzneimittel AG: revenues & profitability
Figure 166: STADA Arzneimittel AG: assets & liabilities
Figure 167: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 168: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 169: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 170: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 171: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 172: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 173: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 174: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities